Vitamin D Supplementation in Obesity and Weight Loss (3DD Study)
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Obesity Weight Loss, Osteoporosis |
| Therapuetic Areas: | Endocrinology, Rheumatology |
| Healthy: | No |
| Age Range: | 50 - 72 |
| Updated: | 3/9/2019 |
| Start Date: | January 2010 |
| End Date: | December 2019 |
A Pilot Dose Response Study to Vitamin D in Obesity and Weight Loss: Effect on Bone
In this study, we will provide supplemental vitamin D in postmenopausal overweight/obese
women, and hypothesize that it will not affect areal BMD, but will alter bone compartments
(trabecular and cortical bone). In addition, higher vitamin D intake will increase serum
25OHD and suppress serum PTH and bone turnover during weight reduction. Secondary outcomes
include the influence of vitamin D and weight loss on markers of insulin resistance and on
cognitive tests of attention, learning, and memory.
women, and hypothesize that it will not affect areal BMD, but will alter bone compartments
(trabecular and cortical bone). In addition, higher vitamin D intake will increase serum
25OHD and suppress serum PTH and bone turnover during weight reduction. Secondary outcomes
include the influence of vitamin D and weight loss on markers of insulin resistance and on
cognitive tests of attention, learning, and memory.
Inclusion Criteria:
- Body mass index of 25-40 kg/m2,
- Postmenopausal,
- Age 50-72 years.
Exclusion Criteria:
- Women who are taking any medication known to influence Ca or bone metabolism, or with
evidence of diseases known to influence Ca metabolism (i.e. metabolic bone disease,
hyperparathyroidism, untreated thyroid disease, significant immune, hepatic, or renal
disease, a kidney stone in the last 5 yrs., significant cardiac disease, active
malignancy or cancer therapy within the past year) are not eligible.
We found this trial at
1
site
Click here to add this to my saved trials
